definiens: means, with respect to the [COMPANY] Product in a ny country in the Territory, that one or more ImmunoGe n Generic Products are or become commercially avail able in such country, and such [COMPANY] Generic Products h ave a market share ( in the aggregate ) of [ * * * ] or g reater in a Calendar Quarter, provided that such [COMPANY] Generic Competition shall be d eemed to exist only for so long as unit volume sales of such [COMPANY] Generic Products in such country, as a percentage of total unit volume sales of [COMPANY] Products and such ImmunoG en Generic Products, during any Calendar Quarter thereafter exceeds [ * * * ], and, if such [COMPANY] Ge neric Product market share falls below [ * * * ] in suc h country, [COMPANY] Generic Competition shall not thereafter be deemed to exist until the unit volume market sha re of [COMPANY] Generic Products again exceeds [ * * * ] . Mar ket share is based on the aggregate market in such country of the [COMPANY] Product and the [COMPANY] Generic Products, based on units of the [COMPANY] Product s old and units of such [COMPANY] Generic Products sold i n the aggregate, as reported by Quintiles / IMS Healt h, or if such data are not available, such other reliable da ta source as reasonably agreed by the Parties